Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects Robert K. OldhamA. Charles MorganKenneth A. Foon OriginalPaper Pages: 51 - 62
The selection of monoclonal antibodies for tumour localization in patients with colorectal carcinoma Karol SikoraThomas AldersonHoward Smedley OriginalPaper Pages: 63 - 71
Generating human monoclonal antibodies A. M. NevilleP. A. W. EdwardsM. J. O'Hare OriginalPaper Pages: 73 - 76
Receptor mediated pathways for interferon action:In vivo implications K. E. MogensenM. -T. BanduP. Eid OriginalPaper Pages: 77 - 85
The clinical application of fibroblast interferon—An overview A. Billiau OriginalPaper Pages: 87 - 96
Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon Charles ChanyItalina Cerutti OriginalPaper Pages: 101 - 107
Inhibition of the growth of some hormone dependent tumors byd-Trp6-LH-RH Andrew V. SchallyTommie W. ReddingAna Maria Comaru-Schally OriginalPaper Pages: 109 - 118
An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma G. MathéM. L. VovanA. V. Schally OriginalPaper Pages: 119 - 122
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments Jan G. M. Klijn OriginalPaper Pages: 123 - 128
Advanced prostatic adenocarcinoma: Biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH G. TolisM. KoutsilierisM. Dufresne OriginalPaper Pages: 129 - 136
Cyclosporine—A model for the testing of bio-immunological reaction modifiers in man R. L. PowlesB. EvansW. Westensee OriginalPaper Pages: 137 - 139
